Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance [RNA-seq]

ABSTRACT: Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance [RNA-seq]

PROVIDER: PRJNA658261 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12482300_1.fastq.gz	Fastqsanger.gz
	SRR12482300_2.fastq.gz	Fastqsanger.gz
	SRR12482301_1.fastq.gz	Fastqsanger.gz
	SRR12482301_2.fastq.gz	Fastqsanger.gz
	SRR12482302_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 120

Similar Datasets

Proteomics analysis of childhood acute lymphoblastic leukemia cell lines reveals novel drug vulnerabilities

Project description:Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and it has a 5-year survival rate of 85% for European children. But for subsets of patients who fail to respond to standard of care chemotherapeutics, treatment options are limited, and clinical prognosis is poor. To establish a platform and methodology to better characterize ALL subtypes and identify their pharmacologic vulnerabilities, we assembled a biobank of 49 readily available childhood ALL cell lines representing diverse immunotypes and genetic profiles. Using these cell lines, we performed comprehensive multi-omic analyses, providing proteomic, transcriptomic and pharmacoproteomic characterization of childhood ALL. We used this resource to characterize the functional impact of genetic fusions and cellular differentiation states on the proteome. Additionally, we identified a novel drug vulnerability in one of the ALL subtypes. Our results are provided as an interactive online data portal with navigable proteomics, transcriptomics, and drug sensitivity profiles.

2022-03-26 | PXD023662 | Pride

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2019-02-25 | PXD010175 | Pride

Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance

Project description:Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance

| PRJNA658345 | ENA

Proteogenomics of High hyperdiploid childhood acute lymphoblastic leukemia

Project description:Proteogenomic analysis and genomic profiling, RNA-sequencing, and mass spectrometry-based analysis of High hyperdiploid childhood acute lymphoblastic leukemia.

2020-01-29 | MSV000084862 | MassIVE

Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance [eRRBS]

Project description:Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance [eRRBS]

| PRJNA658262 | ENA

Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance [ChIP-seq]

Project description:Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance [ChIP-seq]

| PRJNA658349 | ENA

Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia

Project description:We analyzed 52 Diagnostic samples from childhood Acute lymphoblastic leukemia samples

2015-08-11 | GSE69229 | GEO

Transcriptome analysis of childhood acute lymphoblastic leukemia cell lines

Project description:Transcriptome profiling of 49 childhood acute lymphoblastic leukemia cell lines and 2 EBV transformed B-cell lines.

2022-02-16 | GSE168386 | GEO

Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia

Project description:We analyzed 52 Diagnostic samples from childhood Acute lymphoblastic leukemia samples We compared methylation profiles with four ALL cytogentic subtypes using (n=26) long term remission vs. (n=26) that went on to relapse

2015-08-11 | E-GEOD-69229 | biostudies-arrayexpress

Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Role in Drug Resistance [eRRBS]

Project description:B cell acute lymphoblastic leukemia (ALL) is the most common malignancy in children and while highly curable, it remains a leading cause of cancer-related mortality. The outgrowth of tumor subclones carrying mutations in genes responsible for resistance to therapy has led to a Darwinian model of clonal selection. Previous work has indicated that alterations in the epigenome might contribute to clonal selection yet the extent to which the chromatin state is altered under the selective pressures of therapy is unknown. To address this, we performed chromatin immunoprecipitation, gene expression analysis, and enhanced reduced representation bisulfite sequencing on a cohort of paired diagnosis/relapse samples from individual patients who all but one relapsed within 36 months of initial diagnosis. Collectively, our data show that the chromatin state at diagnosis varies widely among patients. While the majority of peaks remained stable between diagnosis and relapse, a significant fraction were either lost or newly gained with some patients showing few differences and others showing massive changes of the epigenetic state. Evolution of the epigenome are associated with pathways previously linked to therapy resistance as well as novel candidate pathways through alterations in pyrimidine biosynthesis and downregulation of polycomb repressive complex 2 targets. We also discovered three novel, relapse-specific super-enhancers shared by a majority of patients including one associated with S100A8, the top upregulated gene seen at relapse in childhood B-ALL. Our results support the role of the epigenome in driving clonal evolution and uncover new candidate pathways associated with relapse.

2020-12-21 | GSE156532 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data